



Wednesday, February 22, 2023

13:00-14:30	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)				
14:30-16:00	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)
16:15-17:45	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)
18:00-19:00	OPENING CEREMONY <u>Tadej Battelino</u> - Opening remarks OPENING LECTURE <u>Chantal Mathieu</u> - The new face of diabetes				
19:00-20:00	NETWORKING RECEPTION (in the Exhibition Area)				

Thursday, February 23, 2023

08:30-10:00	PLENARY SESSION – CGM USE IN TYPE 2 DIABETES AND BEYOND <u>Rich Bergenstal</u> - Use of CGM with people with diabetes type 2 not treated with insulin <u>Lalantha Leelarathna</u> - Use of CGM with people with diabetes type 2 treated with basal insulin only <u>Melissa Putman</u> - Use of CGM in the Cystic Fibrosis population <u>Satish Garg</u> – The vision of the future of CGM in type 2 diabetes
10:00-10:30	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES
10:30-12:00	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)
12:00-13:00	LUNCH BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES

13:00-14:30	PARALLEL SESSION DECISION SUPPORT SYSTEMS	PARALLEL SESSION TECHNOLOGY USE IN PREGNANCY	PARALLEL SESSION EXERCISE IN DIABETES	PARALLEL SESSION RESOLVING HYPOGLYCEMIA	PARALLEL INDUSTRY SYMPOSIUM <small>(not included in the main event CME/CPD credit)</small>	PARALLEL INDUSTRY SYMPOSIUM <small>(not included in the main event CME/CPD credit)</small>	Oral (1)
	<p>Revital Nimri - Real-World Data on the use of Decision Support systems</p> <p>Peter Jacobs - Decision support, incorporating explainability and interpretability</p> <p>Leah Wilson - Artificial intelligence and decision support systems</p> <p>Korey Hood - Patient reported outcomes in closed loop studies</p>	<p>Sarit Polsky - Do we need pregnancy specific closed-loop algorithms?</p> <p>Lois Donovan - Psychosocial impact of using closed-loop systems during pregnancy</p> <p>Helen Murphy - Automated insulin delivery in type 1 diabetes pregnancy - are we nearly there yet?</p> <p>Yariv Yogev - Should we suggest weight loss during pregnancy for obese women with diabetes?</p>	<p>Kirsten Nørgaard - Exercise with AID</p> <p>Dessi Zaharieva - Is technology useful for breaking down barriers to exercise in diabetes?</p> <p>Lia Bally - Physical activity with long and ultra-long-acting basal insulins</p> <p>Ali Cinar - Automated detection of meals and exercise events in people with diabetes</p>	<p>Simon Heller - What reduction in hypoglycemia from interventions should be considered clinically meaningful</p> <p>Pratik Choudhary - Difference between CGM detected and patient reported hypoglycemia</p> <p>Frans Pouwer - The impact of hypoglycemia: what do studies using patient reported outcomes tell us</p> <p>Bastiaan de Galan - Learnings from the HypoRESOLVE</p>			
14:30-15:00	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
15:00-16:30	INDUSTRY SYMPOSIUM <small>(not included in the main event CME/CPD credit)</small>						

16:40-18:00	PARALLEL SESSION EMERGING TREATMENT OPTIONS FOR OBESITY AND TYPE 2 DIABETES	PARALLEL SESSION JDRF SESSION - CONTINUOUS KETONE MONITORING FOR TYPE 1 DIABETES	PARALLEL SESSION AID EXPERIENCE IN THE REAL- WORLD IN: -	PARALLEL SESSION CLOSED-LOOP IN ACTION	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	Oral (2)
	<p><u>Mojca Jensterle Sever</u> - GLP-1 Analogs for the treatment of Obesity</p> <p><u>Juan Frias</u> - Unimolecular multiagonists (dual and triple) for the management of obesity and cardiorenal risk – An update</p> <p><u>Julio Rosenstock</u> - Challenging Treatment Guidelines: Reversing Type 2 DM from Day One</p> <p><u>Walter Pories</u> - Bariatric surgery: an update</p>	<p>TBD: Clinical need for continuous ketone monitoring integrated into CGM devices (i.e. CGM-CKM)</p> <p><u>Rodica Busui:</u> SGLT inhibitors in T1D: DKA risk and DKA risk mitigation strategies, especially CGM-CKM, to enable therapy use for heart and kidney health</p> <p><u>Idan Tamir:</u> pre-clinical development of CGM-CKM</p> <p><u>Shridhara Alva:</u> pre-clinical and clinical development of CGM-CKM</p>	<p><u>Eric Renard</u> – French Children</p> <p><u>Regis Radermecker</u> – In Belgium</p> <p><u>Emma Wilmot</u> – in the United Kingdom</p> <p><u>Helen Murphy</u> – in pregnancy</p>	<p><u>Roman Hovorka</u> - Closing the loop – from cradle to mature age</p> <p><u>Ahmad Haidar</u> - Closed-loop with adjunct therapies</p> <p><u>Stuart Weinzimer</u> - Postprandial glucose control in advanced hybrid closed-Loop systems</p> <p><u>Peter Jacobs</u> - Closed-loop next generation algorithms, leveraging AI and the smart-home</p>			

Friday, February 24, 2023

08:00-08:50	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)						
09:00-10:00	PARALLEL SESSION DERMATOLOGY IN DIABETES	PARALLEL SESSION WEEKLY INSULINS	PARALLEL SESSION CARDIOVASCULAR DIABETES	PARALLEL SESSION NON-INVASIVE GLUCOSE MONITORING: REALITY VS. HYPE	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	Oral (3)
	<p>Irl Hirsch - Skin and the Insulin Pump: New Findings</p> <p>Laurel Messer - Skin integrity, tips, tricks and hacks for sustained device use</p> <p>Sumita Pennathur - Long term solutions for improving infusion site challenges for insulin pumps</p>	<p>Julio Rosentock - Update on Weekly Icodec Insulin: Lessons from the ONWARD Clinical Development Program</p> <p>Steven Edelman - Once weekly insulins in Type 1 diabetes: safety, efficacy and does it address an unmet need?</p> <p>Juan Frias - Once Weekly Basal Insulin Fc (BIF): An Update on the Type 2 Diabetes Clinical Development Program</p>	<p>Antonio Ceriello - Cardiovascular outcome trials (CVOT): which role for risk factors control?</p> <p>Oliver Schnell - Cardiovascular outcome trials (CVOTs) in diabetes - A success story that has changed the landscape of diabetes therapy</p> <p>Viral Shah - Causes of cardiovascular disease and insulin resistance in type 1 diabetes</p>	<p>Bruno Thuillier - Non-invasive Glucose Monitoring: Breath, a realistic option?</p> <p>Christophe de Block - Continuous Ketone Monitoring</p> <p>Anders Weber - Raman Ni-BGM from conception to real world clinical device; are we there yet?</p>			
10:00-10:30	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
10:30-12:00	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)						
12:00-13:00	LUNCH BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						

13:00-14:30	ATTD YEARBOOK SESSION						
14:30-15:00	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
15:00-16:30	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)						
16:40-18:00	<p>PARALLEL SESSION ADVANCES IN FULLY AUTOMATED CLOSED-LOOP</p> <p>Patricio Colmegna - Automated control meets behavior: human-machine co-adaptation of the artificial pancreas</p> <p>Michael Riddell - Closing the loop on exercise</p> <p>Klemen Dovc - Ultra-rapid insulin and anticipatory algorithms</p> <p>Boris Kovatchev - Fully-automated closed-loop control: challenges and potential solutions</p>	<p>PARALLEL SESSION TIMES IN RANGES</p> <p>Thomas Danne - What is the clinical relevance of TIR/TAR 70-140 mg/dl for T1D and T2D?</p> <p>Peter Adolfsson – Time in tight range in type 1 diabetes</p> <p>Tadej Battelino – Time in tight range in type 2 diabetes</p> <p>David Rodbard –TIR and other Times in Ranges are better than HbA1c as metrics for quality of glycemic control</p>	<p>PARALLEL SESSION FEAR OF HYPERGLYCEMIA</p> <p>Bruce Bode - Management of Hyperglycemia in the hospital using closed-loop systems</p> <p>Irl Hirsch - Update on glycemic targets in the ICU</p> <p>Nataša Bratina – Avoiding hyperglycemia from diabetes onset</p> <p>Alon Liberman – Fear of hyperglycemia in parents of children with type 1 diabetes</p>	<p>PARALLEL SESSION TECHNOLOGY FOR THE HEALTHY AGING OF OLDER PEOPLE WITH DIABETES</p> <p>Medha Munshi - Why healthy aging with diabetes is a challenge?</p> <p>Tali Cukierman-Yaffe - Adverse outcomes of hyperglycemia & hypoglycemia in older people with diabetes-how should the recommended target % TIR be determined?</p> <p>Richard Pratley - The use of CGM in older people with diabetes</p> <p>David O’Neal - The use of Hybrid closed systems in older people with diabetes</p>	<p>PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)</p>	<p>PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)</p>	<p>Oral (4)</p>
18:15-19:45	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)						

Saturday, February 25, 2023

08:00-09:10	INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)						
09:30-11:00	PARALLEL SESSION REMOTE TREATMENT OF DIABETES	PARALLEL SESSION NUTRITION AND FOOD TECHNOLOGIES	PARALLEL SESSION DESPAIR AND SELF-HARM & DIABETES TECHNOLOGY	PARALLEL SESSION PRACTICAL ISSUES IN DAILY LIFE OF PEOPLE WITH DIABETES	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	Oral (5)	Oral (6)
	<p>Mark Clements – Population health management in the digital diabetes era</p> <p>Paul Wadwa - Challenges in implementing telehealth for diabetes care</p> <p>David Maahs - ECHO study - Delivering tele-education on diabetes to primary care physicians in rural areas</p> <p>Robert Ratner - Outcomes of Continuous Remote Care in Pre-diabetes and type 2 Diabetes</p>	<p>Andrea Scaramuzza – Strategies for mitigating glycemic excursions following unannounced meals with existing technologies</p> <p>Maya Laron-Hirsh - Complex meal handling with advanced hybrid closed-Loop system</p> <p>Maria Vasiloglou - What healthcare professionals and end-users need in image-based nutrition apps</p> <p>Michal Gillon-Keren Mobile application for carbohydrate counting - personalized nutrition</p>	<p>Lori Laffel - Addressing opportunities to Improve glycemic control and limit diabetes distress</p> <p>Katharine Barnard-Kelly - Understanding clinical relevance on a PRO</p> <p>Marc Breton - Machine learning and big data to identify individuals at risk</p> <p>Marissa Town - What matters to the person with diabetes when choosing diabetes technologies</p>	<p>John Pemberton - The issues with using CE Mark as a valid proxy for continuous glucose monitoring systems accuracy for people with type 1 diabetes</p> <p>Emma Wilmot - Helping adults choose a safe and effective CGM in light of new national guidance</p> <p>Ramzi Ajjan - Is it easy to use time in range (TIR) for daily management of diabetes?</p> <p>Mark Evans - The regulations around driving and diabetes</p>			

11:00-11:30	COFFEE BREAK, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES						
11:30-13:00	PARALLEL SESSION FIGHTING DISPARITIES	PARALLEL SESSION JDRF SESSION	PARALLEL SESSION DATA SCIENCE IN DIABETES	PARALLEL SESSION GLUCOSE MANAGEMENT IN THE PEDIATRIC AND ADULT FEMALE POPULATION	PARALLEL SESSION DIABETES INDIA	Oral (7)	Oral (8)
	<p><u>Lori Laffel</u> - Understanding and overcoming Health disparities in use of diabetes technologies</p> <p><u>Partha Kar</u> - Strategies to tackle the deprivation gap in tech access</p> <p><u>David Maahs</u> - Bridging Disparities in Type 1 Care in the US</p> <p><u>Viswanathan Mohan</u> - Advocacy and adoption of technology and disparities in India</p>		<p><u>Amy Criego</u> - Improved data collection: moving CGM reports from the patient directly to the EMR</p> <p><u>David Scheinker</u> - Algorithm-enabled RPM for T1D; lessons from the 4T study for a continuously learning health system</p> <p><u>Gregory Forlenza:</u> Data ownership and use of data aggregators in clinical care</p> <p><u>Mark Clements</u> - Deep learning to predict diabetes outcome</p>	<p><u>Eda Cengiz</u> - Technological gadgets: What is available to girls and women with diabetes</p> <p><u>Darja Šmigoc Schweiger</u> - Gender differences in cardiovascular risk markers in young population with type 1 diabetes</p> <p><u>Dessi Zaharieva</u> - Sex differences in the management of exercise in the pediatric and adult population</p> <p><u>Chiara Fabris</u> - Insulin dosing in women with T1D: Is there a need for tailored solutions?</p> <p><u>Katharine Barnard – Kelly</u> - Psycho-behavioral barriers to optimal glucose management in women with T1D across the ages</p>	<p><u>Banshi Saboo</u> - Introduction</p> <p><u>Amit Gupta</u> - Personalized medicine to precision medicine: India is changing</p> <p><u>Rakesh Parikh</u> - Diabetes technology - the make in India story</p> <p><u>Manoj Chawla</u> - Diabetes management in India - challenges & tech solutions</p> <p><u>Mithun Bhartia</u> - Swot (strength, weakness, opportunity and threats) analysis of blood sugar monitoring in India</p> <p><u>Jothydev Kesavadev</u> - Do it yourself artificial pancreas: the affordable Indian experience</p>		

13:00-13:45	LUNCH, EXHIBITION & E-POSTERS, INTERNATIONAL FAIR OF NEW TECHNOLOGIES IN DIABETES					
13:45-14:35	PARALLEL SESSION EMERGING TECHNOLOGIES FOR DIABETES	PARALLEL SESSION ISPAD SESSION	PARALLEL SESSION MIND THE FOOT!	PARALLEL SESSION DIABETES TECHNOLOGY AND WASTE: HOW TO TURN GREENER?	TECHFAIR Grant winners' presentations	ORAL (9)
	<p><u>Simon Friedman</u> – Replacing Pumps with Light Controlled Insulin Delivery</p> <p><u>Idan Tamir</u> - Continuous Lactate Monitoring (CLM) – a new paradigm for monitoring high-risk diabetic patients</p> <p><u>TBD</u></p>	<p><u>TBD</u> -Global Registry data: Diabetes Technology impact</p> <p><u>Julia Lawton</u> - Psychological impact of technology: what is most relevant?</p> <p><u>Jamie Wood</u> - Diabetes technology access in low and middle low-income countries: now or later</p>	<p><u>Andrew Boulton</u> - New evidence-base therapies for complex diabetic foot wounds</p> <p><u>Julia Mader</u> - Monitoring of diabetic foot disease</p> <p><u>Prash Vas</u> - Developing a Functional Multidisciplinary foot service of the future: Integrating team working and technology</p>	<p><u>David Kerr</u> - The Greening of Diabetes Care in America</p> <p><u>Lutz Heinemann</u> - Diabetes technology and waste: how to turn greener? - The EU point of view</p> <p><u>Matthias Axel Schweitzer</u> - Diabetes technology and waste: how to turn greener? - The manufacturers' point of view</p>		

14:45–15:45	PLENARY SESSION SCREENING AND PREVENTION OF TYPE 1 DIABETES <u>Rachel Besser</u> – Screening of general population – current status around the world <u>Laura Jacobsen</u> – Emerging biomarkers of responses to immunotherapies <u>Jay Skyler</u> – Stem Cell Approaches to Type 1 Diabetes
15:45-16:15	CLOSING REMARKS 100 YRS INSULIN PRIZE
15:45-16:15	FAREWELL REFRESHMENTS